摘要
目的:探讨并分析用吉非替尼对老年晚期肺癌患者进行治疗的临床效果。方法:选择2017年12月至2018年12月临沂市罗庄中心医院收治的82例老年晚期肺癌患者作为研究对象,按照其住院病历尾号的奇偶数将其分为观察组(n=41)与对照组(n=41)。用紫杉醇联合顺铂对对照组患者进行治疗,用吉非替尼对观察组患者进行治疗,然后比较两组患者的近期疗效、用药后不良反应的发生率及其血清癌胚抗原(CEA)的水平。结果:观察组患者病情的客观缓解率高于对照组患者,差异有统计学意义,P<0.05。用药后,观察组患者不良反应的发生率低于对照组患者,差异有统计学意义,P<0.05。治疗1个周期、2个周期、3个周期及4个周期后,观察组患者血清CEA的水平均低于对照组患者,差异有统计学意义,P<0.05。结论:用吉非替尼对老年晚期肺癌患者进行治疗的效果较好,能缓解其病情,改善其血清CEA的水平,且用药的安全性较高。
Objective:To investigate and analyze the clinical effect of gefitinib in the treatment of elderly patients with advanced lung cancer.Methods:A total of 82 elderly patients with advanced lung cancer admitted to Luozhuang Central Hospital of Linyi city from December 2017 to December 2018 were selected as study subjects,and were divided into observation group(n=41)and control group(n=41)according to the odd Numbers at the end of their inpatient medical records.Patients in the control group were treated with paclitaxel combined with cisplatin,and those in the observation group were treated with gefitinib,and the short-term efficacy,incidence of adverse reactions after administration,and serum CEA levels were compared between the two groups.Results:The objective remission rate of patients in the observation group was higher than that in the control group,the difference was statistically significant(P<0.05).After treatment,the incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).After 1,2,3 and 4 cycles of treatment,serum CEA levels in the observation group were all lower than those in the control group,with statistically significant difference(P<0.05).Conclusion:Gefitinib is effective in the treatment of elderly patients with advanced lung cancer,which can alleviate their condition,improve their serum CEA level,and the safety of the drug is relatively high.
作者
王君芳
Wang Junfang(Department of Tumor Interventional Therapy,Luozhuang Central Hospital,Linyi,Shandong 276000)
关键词
吉非替尼
晚期肺癌
老年患者
紫杉醇
顺铂
不良反应
血清癌胚抗原
Gefitinib
Advanced lung cancer
Elderly patients
Taxol
Cisplatin.Adverse reactions
Serum carcinoembryonic antigen
